Can I still switch to another drug after capmatinib resistance? What’s the next step in treatment?

Although Capmatinib (Capmatinib) has a good effect in treating METex14 mutated lung cancer, some patients may develop drug resistance after using it for a period of time. Reasons for drug resistance may include further mutations in the MET gene, activation of alternative signaling pathways (such as EGFR, KRAS, etc.) or histological transformation of tumors. According to different resistance mechanisms, the next treatment options are also different. If the MET gene is further mutated, you can consider replacing it with a new MET inhibitor, such as Tepotinib or the next generation MET inhibitor under research. If the bypass pathway is activated, it may be necessary to combine targeted drugs such as EGFR, MEK or ALK. In addition, some patients may consider chemotherapy or immunotherapy, especially patients with high PD-L1 expression may benefit from immunotherapy.